Skip to content
drillr.ai
Sign up

BNTX

BioNTech SE

NASDAQ · Healthcare · Biotechnology · DE

$96.06
−2.64%
Ask drillr

  • Sep 17, 2026, 17:30 UTC

    Health Canada approved the Pfizer-BioNTech COVID-19 vaccine adapted for the Omicron XBB variant.

    Source:

  • Sep 14, 2026, 08:00 UTC

    BioNTech and OncoC4 announced updated data from the non-pivotal stage 1 of the PRESERVE-003 Phase 3 trial showing gotistobart nearly doubled median overall survival versus standard-of-care chemotherapy in previously treated squamous non-small cell lung cancer patients.

    Source:

  • Aug 28, 2026, 13:17 UTC

    BioNTech announced the termination of its Phase 2 clinical trial for colorectal cancer.

    Source:

  • Aug 27, 2026, 20:30 UTC

    The U.S. FDA approved the supplemental Biologics License Application for Pfizer and BioNTech's 2026-2027 COVID-19 vaccine formula targeting the XFG variant, for use in adults aged 65 and older and individuals aged 5-64 with high-risk conditions.

    Source:

  • Aug 20, 2026, 09:30 UTC

    BioNTech presented first global clinical data for its new dual-drug combination of Pumitamig and Elfetabart Drozuntecan in advanced lung cancer at the 2026 World Conference on Lung Cancer.

    Source:

  • Aug 11, 2026, 07:00 UTC

    Bios Life announced a multi-year partnership with Tempus, including commercial rights to BioNTech-InstaDeep's genomics AI.

    Source:

  • Aug 6, 2026, 11:00 UTC

    Genevant and Arbutus received $950 million from Moderna in July 2026 under a $2.25 billion settlement, with additional $1.3 billion contingent on appeal resolution, and filed new international lawsuits against Pfizer and BioNTech covering 21 jurisdictions.

    Source:

  • Aug 4, 2026, 10:45 UTC

    BioNTech reported second quarter 2026 financial results with revenues of €105.6 million and revised its full year 2026 revenue guidance to €1.6–1.9 billion.

    Source:

  • Aug 3, 2026, 09:29 UTC

    BioNTech announced on Monday that Guido Oelkers, CEO of Sobi, will succeed Ugur Sahin as its chief executive.

    Source:

  • Jul 29, 2026, 20:30 UTC

    The European Commission granted marketing authorization for Pfizer and BioNTech's 2026-2027 COVID-19 vaccine formula targeting the XFG variant in the European Union.

    Source:

  • Jul 16, 2026, 11:30 UTC

    Arbutus Biopharma and its licensee Genevant filed three international patent infringement lawsuits against Pfizer and BioNTech.

    Source:

  • Jun 17, 2026, 06:38 UTC

    Moderna expressed interest in investing in production facilities in Germany, potentially acquiring plants that BioNTech plans to close.

    Source: